Crinum Latifolium (CL) is a well-known plant known for its anti-oxidant, antiinflammatory and anti-arthritic activity belonging to family Amaryllidaceae. Leaves part of that has tremendous anti-arthritic activity. The objective of this study was to formulate a topical nanoemulgel formulation from methanolic extract of Crinum Latifolium for the treatment of rheumatoid arthritis (RA) with the intention of minimizing the systemic side effects. First, the methanolic extract of Crinum Latifolium (MCL) was obtained by Maceration method. The nanoemulsion formulation of Crinum Latifolium methanolic extract (NE-MCL) was prepared through the hot emulsification method followed by homogenization technique. The optimization of surfactant and co-surfactant concentration was carried out using phase diagrams method and found that is able to formulate a stable emulsion. This ratio was further investigated for the process parameters i.e. Oil: Smix (X1), stirring speed (X2), and stirring time (X3). The final optimized formulation was found to have particle size (PS) of 225 nm and polydispersity index of 0.128 and zeta potential of -3.198mV with a desirability of 0.846. The optimized formulation was consisted of 98.33 ± 0.69% drug content. In vitro drug release studies showed that about 80% of the MCL was released in 24 hrs from the NE-MCL represented its sustained release effect. The TEM micrograph showed a perfectly spherical shaped particles in nano size range. The NE-MCL gel (NEG-MCL) was formed using Carbopol ETD 2020 and the pH was measured. The pH was found to have a value of 5.78 ± 0.12, ensuring that no bacterial growth or tissue irritation occurs due to pH fluctuations. The spreadability and viscosity of the nanoemulgel formulation was found to be 22.84 cm and 247.10 ± 1.3 cps respectively. The in vitro drug release of nanoemulgel formulation was compared to plain Nanoemulsion formulation and found that Nanoemulgel showed a better sustained release effect compared to plain Nanoemulsion formulation. Also, the R2 value for zero order, first order, Higuchi model and Koresmeyer Peppas model was found to be 0.782, 0.815, 0.912 and 0.892 respectively which showed that the drug was release by diffusion-controlled mechanism from the matrix. These results showed that nanoemulgel formulation is capable to provide a sustained release formulation which in turn helped in reducing the dosage and dosing frequency and thereby, reduces the adverse effects of MCL.